Information Provided By:
Fly News Breaks for May 16, 2019
BLUE
May 16, 2019 | 09:46 EDT
SunTrust analyst Edward Nash lowered his price target on Bluebird Bio to $174 to reflect the changes in his model after the company's Analyst Day presentation. The analyst is pushing back his expected Lenti-D start year to 2020 from 2019 and also raising his assumed R&D and SG&A expenses while also removing the revenue projections for the company's B-thalassemia patients aged below 12 in the U.S. and E.U. Nash is also keeping his Buy rating on Bluebird Bio, saying he sees the company as "best positioned" in transforming gene therapy from a "scientific endeavor" to a "successful proposition."